The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Myoinositol versus metformin pretreatment in GnRH-antagonist cycle for women with PCOS undergoing IVF: a double-blinded randomized controlled study
Abstract
OBJECTIVE: To study the effects of myoinositol (Myo) in comparison to metformin (Met), in reducing the risk of OHSS and improving ART outcome in PCOS women undergoing IVF. DESIGN: Double-blinded randomized controlled trial (CTRI/2018/05/014196). SETTING: ART Clinic, AIIMS, New Delhi patients: 102 infertile PCOS women undergoing IVF cycles were enrolled after evaluating for eligibility and allotted as 50 in group 1 (Myo) and 52 in group 2 (Met) after randomization. INTERVENTIONS: Recruited patients received Myo 2 g twice daily (group 1) and Met 850 mg twice daily (group 2). Pre- and post-treatment clinical (menstrual pattern, BMI), hormonal profile (LH, FSH, testosterone, prolactin [PRL], and AMH), biochemical parameters (HOMA IR, fasting glucose, and insulin), ovarian with antral follicle count (AFC) and side effect profile were assessed. After 3 months of therapy, patients were recruited for IVF cycle by antagonist protocol was involving controlled ovarian stimulation, cycle monitoring, oocyte recovery, insemination of oocytes and follow up with fertilization, cleavage, transfer of good grade cleavage embryos, or blastocysts pregnancy outcomes and OHSS incidence and medications was continued until the day of OPU. MAIN OUTCOME MEASURES: Primary outcome was OHSS and clinical pregnancy rate including spontaneous, IVF, and cumulative pregnancy rate including FET. Secondary outcome was ART outcomes and the change in biochemistry and hormonal profile between groups and inter group after medications at 12 weeks. RESULTS: .07) was significantly high in Myo group. No between group difference in ovarian stimulation outcomes including duration and dosage of gonadotropins, E2, P4 levels, number of follicles >14 mm on day of trigger. Number of oocytes retrieved and grade of maturity were similar between groups. Fertilization, cleavage and number of good grade embryos were significantly higher in Myo group. However, implantation rate and number of embryos for freezing were similar between groups. Myo had improvement in fasting insulin, HOMA, Sr.AMH, and SHBG suggesting decreased insulin resistance. CONCLUSIONS: Myo is equally beneficial as Met in reducing the risk of OHSS and has better ART outcome in PCOS women undergoing antagonist cycles.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Ten studies specifically enrolled women with PCOS who also had infertility (25, 27, 40, 46-51, 55, 56).”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [51]
In the citing paper
“Twelve used metformin at doses of 1000 mg to 2000 mg daily alone or in combination with FA as a comparator (26, 28, 30, 33, 39, 41, 42, 49-54, 56).”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [51]
In the citing paper
“There were no differences between groups for metabolic, lipid, and most anthropometric outcomes including fasting glucose (Fig. 5D, 4 studies) (26, 41, 42, 51, 53), fasting insulin (Fig. 5E, 5 studies) (26, 30, 41, 42, 51, 53), HOMA-IR (Fig. 5F, 5 studies) (26, 33, 41, 42, 51, 53), total cholesterol, HDL, and LDL cholesterol (Fig. 5G–5I, 2 studies) (41, 42, 51), weight (Fig. 5J, 3 studies) (30, 41”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [51]
In the citing paper
“In meta-analysis for androgenicity, metformin was superior to MI for FG score in 2 trials (MD 2.42, Fig. 5A) (26, 53), while MI was superior to metformin for SHBG (MD 3.85, Fig. 5C, 2 studies) (26, 53), with no differences in total testosterone in 4 trials (Fig. 5B) (26, 41, 42, 51, 53).”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [51]
In the citing paper
“Reproductive outcomes including resumption of normal menstrual cycles (Fig. 5N, 3 studies) (26, 33, 51) or rate of ovulation (Fig. 5O, 2 studies)(49, 50) did not differ between groups.”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [51]
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
1 retracted
Papaleo, E., Unfer, V., Baillargeon, J.-P., Fusi, F., Occhi, F., & De Santis, L. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.01.088 · Cited by 197 · cited 1×
“maturation and quality with improved fertilization rate during IVF cycles [8].”
BackgroundRetractedThe Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2004) · Human Reproduction · doi:10.1093/humrep/deh098 · Cited by 6,138
The Istanbul consensus workshop on embryo assessment: proceedings of an expert meeting
Alpha Scientists in Reproductive Medicine and ESHRE Special Interest Group of Embryology, Balaban, B., Brison, D., Calderon, G., Catt, J., Conaghan, J., Cowan, L., Ebner, T., Gardner, D., Hardarson, T., et al. (2011) · Human Reproduction · doi:10.1093/humrep/der037 · Cited by 2,015
Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS
Kahsar-Miller, M. D., Nixon, C., Boots, L. R., Go, R. C., & Azziz, R. (2001) · Fertility and Sterility · doi:10.1016/s0015-0282(00)01662-9 · Cited by 406 · cited 1×
“Chronic anovulation is the key reason for menstrual irregularities and infertility in women with PCOS in reproductive years [4].”
BackgroundDiamanti-Kandarakis, E., Christakou, C. D., Kandaraki, E., & Economou, F. N. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-0733 · Cited by 247 · cited 1×
“Met, an oral biguanide, acting by both direct and indirect mechanisms, can mediate ovarian response to gonadotropins, reducing the risk of OHSS [18] in agonist cycle.”
BackgroundJoshi, B., Mukherjee, S., Patil, A., Purandare, A., Chauhan, S., & Vaidya, R. (2014) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.131162 · Cited by 228 · cited 1×
“Polycystic ovarian syndrome (PCOS) is the most common endocrine disorder affecting 6 10% of women in reproductive age group [1,2].”
BackgroundThe use of metformin for women with PCOS undergoing IVF treatment
Tang, T., Glanville, J., Orsi, N., Barth, J. H., & Balen, A. H. (2006) · Human Reproduction · doi:10.1093/humrep/del025 · Cited by 214 · cited 1×
“clinical pregnancy rates in PCOS women with subfertility [6].”
BackgroundReview: Role of metformin in the management of polycystic ovary syndrome
Lashen, H. (2010) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018810380215 · Cited by 173
Medicine, A. S. I. R. (2012) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2012.05.006 · Cited by 139
The role of AMH in anovulation associated with PCOS: a hypothesis
Homburg, R., & Crawford, G. (2014) · Human Reproduction · doi:10.1093/humrep/deu076 · Cited by 115 · cited 1×
“0 ng/ml [24] being associated with adverse response to stimulation including poor response.”
Background
Research works printed but not linked: 5
- Tso LO, 2014, Cochrane Database Syst Rev, CD006105
- Showell MG, 2018, Cochrane Database Syst Rev, 12, CD012378
- Smith V, 2020, Obstet Gynecol Int, 2015, 12
- Mourad S, 2017, Cochrane Database Syst Rev, 1, CD012103
- Morley LC, 2017, Cochrane Database Syst Rev, 11, CD003053
Cited by
Greff, D., Juhász, A. E., Váncsa, S., Váradi, A., Sipos, Z., Szinte, J., Park, S., Hegyi, P., Nyirády, P., Ács, N., et al. (2023) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-023-01055-z · Cited by 143
Fitz, V., Graca, S., Mahalingaiah, S., Liu, J., Lai, L., Butt, A., Armour, M., Rao, V., Naidoo, D., Maunder, A., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad762 · Cited by 70
“5E, 5 studies) (26, 30, 41, 42, 51, 53), HOMA-IR (Fig.”
BackgroundMethodInfluentialMyo-inositol in assisted reproductive technology from bench to bedside
Etrusco, A., Laganà, A. S., Chiàntera, V., Buzzaccarini, G., & Unfer, V. (2023) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2023.09.005 · Cited by 48
Palomba, S., Costanzi, F., Nelson, S. M., Besharat, A. R., Caserta, D., & Humaidan, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814185 · Cited by 35
“The risk of bias was low (rRoB 2) [49].”
InfluentialMinimising OHSS in women with PCOS
Leathersich, S. J., Roche, C., & Hart, R. J. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1507857 · Cited by 32
Metadata
- Authors
- Rajasekaran, K., Malhotra, N., Mahey, R., Khadgawat, R., & Kalaivani, M.
- Affiliations
- All India Institute of Medical Sciences (IN)
- Corresponding author
- Malhotra, Neena
- Venue
- Gynecological Endocrinology
- Publisher
- Informa UK Limited
- Published
- 2021-09-30
- Volume
- 38
- Issue
- 2
- Pages
- 140-147
- ISSN
- 0951-3590 (ISSN-L)
- 1473-0766
- OpenAlex
- W3203102447
- Cited by
- 22
- References
- 18
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 4 · 2023: 6 · 2022: 1
- FWCI
- 2.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Gynecological Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Reproductive Medicine › Reproductive Biology and Fertility
- Health Sciences › Medicine › Reproductive Medicine › Reproductive Health and Technologies
- Keywords
- myo-inositol, metformin, polycystic ovary syndrome, in vitro fertilization, GnRH antagonist protocol, ovarian hyperstimulation syndrome, insulin resistance, HOMA-IR, androgen-binding protein, antral follicle count, clinical pregnancy rate, embryo quality, controlled ovarian stimulation, assisted reproduction outcomes, insulin sensitizers, insulin-mimetic agents
- MeSH terms
- Female, Fertilization in Vitro, Humans, Inositol, Gonadotropin-Releasing Hormone, Metformin, Ovulation Induction, Polycystic Ovary Syndrome, Pregnancy, Ovarian Hyperstimulation Syndrome, Pregnancy Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Myoinositol versus metformin pretreatment in GnRH-antagonist cycle for women with PCOS undergoing IVF: a double-blinded randomized controlled study. https://app.cochat.ai/papers/10.1080/09513590.2021.1981282
- The paper
- Rajasekaran, K., Malhotra, N., Mahey, R., Khadgawat, R., & Kalaivani, M. (2022). Myoinositol versus metformin pretreatment in GnRH-antagonist cycle for women with PCOS undergoing IVF: a double-blinded randomized controlled study. Gynecological Endocrinology. https://doi.org/10.1080/09513590.2021.1981282
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.